The former chief executive officer of Sydney’s Parramatta Council is suing Fairfax Media, saying three articles published in the Sydney Morning Herald accusing him of lying on his resume were defamatory.
Shenzen-based radio manufacturer Hytera Communications has lost a bid to circumvent its discovery obligations in an ongoing patent dispute with Motorola, with a Federal Court judge rejecting its claims that supplying the documents could breach Chinese state secret and cybersecurity laws.
The Daily Telegraph publisher Nationwide News has lost a bid to amend its defence in Geoffrey Rush’s defamation case to include evidence from an unnamed witness it claimed would support the imputation that Rush engaged in sexual misconduct, with the judge saying the prejudice to Rush would be “manifest and palpable”.
Billionaire Clive Palmer has succeeded in knocking a second judge off a case brought against him by the liquidators of failed Queensland Nickel, after arguing that a previous ruling disqualified him.
A subsidiary of US-based PetroHunter Energy has defeated calls to toss its case over $70 million in allegedly unpaid contributions and contractual breaches stemming from a joint mining venture in the Northern Territory’s Beetaloo Basin.
The Commonwealth of Australia is weighing a bid to strike out Otsuka Pharmaceutical’s defence as the government seeks lost subsidies after an almost seven-year long patent dispute over the antipsychotic drug, Abilify.
An education provider calling itself Trinity College Australia faces a lawsuit alleging it is duping consumers by trying to pass off as The University of Melbourne’s famed residential college.
The Australian Securities and Investments Commission has secured almost $9 million in penalties against Melbourne-based Financial Circle over a scheme to extract advice fees and ongoing commission from borrowers who took out personal loans.
Australian coffee maker Vittoria Food & Beverage has won another challenge to a patent for a coffee pod system filed by a unit of Mondelez International.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.